InVivoMAb Anti-HIV1 env/Env polyprotein Broadly Neutralizing Antibody (Iv0114)

Catalog No.

VVV03105

Species reactivity

Human immunodeficiency virus 1

Host species

Human

Isotype

IgG1

Clonality

Monoclonal

Target

Envelope glycoprotein gp160, Env polyprotein, Surface protein gp120, SU, Glycoprotein 120, gp120, Transmembrane protein gp41, TM, Glycoprotein 41, gp41, env, HIV1, HIV-1

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q03805

Applications

Neutralization

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0114

Afucosylated broadly neutralizing antibodies targeting the HIV envelope elicit enhanced NK-cell-mediated cytotoxicity against HIV-infected CD4+ T-cell and macrophage targets., PMID:40086815

Current methods for detecting and assessing HIV-1 antibody resistance., PMID:39835119

Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies., PMID:39489734

Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions., PMID:39343065

Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs., PMID:39136461

Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates., PMID:37531955

Synthesis and Immunological Evaluation of Pentamannose-Based HIV-1 Vaccine Candidates., PMID:35470665

Covalent coupling of HIV-1 glycoprotein trimers to biodegradable calcium phosphate nanoparticles via genetically encoded aldehyde-tags., PMID:34968725

Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses., PMID:34668778

Mutational fitness landscapes reveal genetic and structural improvement pathways for a vaccine-elicited HIV-1 broadly neutralizing antibody., PMID:33649208

A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls., PMID:33640794

Engineering antibody-based molecules for HIV treatment and cure., PMID:32732551

Serum alpha-mannosidase as an additional barrier to eliciting oligomannose-specific HIV-1-neutralizing antibodies., PMID:32371950

Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion., PMID:31564450

Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model., PMID:31391322

Anti-idiotypic antibodies elicit anti-HIV-1-specific B cell responses., PMID:31345931

eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody., PMID:31068428

Improvement of antibody functionality by structure-guided paratope engraftment., PMID:30760721

Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV., PMID:30518644

HIV-1 cell-to-cell transmission and broadly neutralizing antibodies., PMID:30055632

Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry., PMID:29976677

HIV-1 latent reservoir size and diversity are stable following brief treatment interruption., PMID:29911997

Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies., PMID:29881382

Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site., PMID:29515029

Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections., PMID:29505593

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells., PMID:29237833

Targeted N-glycan deletion at the receptor-binding site retains HIV Env NFL trimer integrity and accelerates the elicited antibody response., PMID:28902916

Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo., PMID:28847869

Potent In Vivo NK Cell-Mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-Bispecific and Hexavalent Broadly Neutralizing Fusion Protein., PMID:28794022

Non-neutralizing Antibodies Alter the Course of HIV-1 Infection In Vivo., PMID:28757252

Engineering antibody-like inhibitors to prevent and treat HIV-1 infection., PMID:28422793

New Connections: Cell-to-Cell HIV-1 Transmission, Resistance to Broadly Neutralizing Antibodies, and an Envelope Sorting Motif., PMID:28250119

Peptide Paratope Mimics of the Broadly Neutralizing HIV-1 Antibody b12., PMID:28125767

Isolation and characterization of an HIV-1 envelope glycoprotein-specific B-cell from an immortalized human naïve B-cell library., PMID:28073404

Effect of HIV-1 Env on SERINC5 Antagonism., PMID:27928004

First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses., PMID:27894306

First Membrane Proximal External Region-Specific Anti-HIV1 Broadly Neutralizing Monoclonal IgA1 Presenting Short CDRH3 and Low Somatic Mutations., PMID:27481846

Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency., PMID:27315478

Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques., PMID:27247400

High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells., PMID:27210756

Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41., PMID:26957202

Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice., PMID:26907590

HIV-1 Vaccine-elicited Antibodies Reverted to Their Inferred Naive Germline Reveal Associations between Binding Affinity and in vivo Activation., PMID:26879974

Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities., PMID:26762799

Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10., PMID:26378169

Gp120/CD4 blocking antibodies are frequently elicited in ART-naïve chronically HIV-1 infected individuals., PMID:25803681

HIV-1 envelope glycoprotein trimer immunogenicity elicited in the presence of human CD4 alters the neutralization profile., PMID:25245278

Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity., PMID:25215485

HIV-1 Env-specific memory and germinal center B cells in C57BL/6 mice., PMID:25198199

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection., PMID:25119033

Document Download

InVivoMAb Anti-HIV1 env/Env polyprotein Broadly Neutralizing Antibody (Iv0114).pdf